Metachromatic Leukodystrophy
New metachromatic leukodystrophy research, summarized each month in plain language.
2026 so far: So far in 2026 (January-September), registry data supported doing allogeneic HSCT earlier in late-onset MLD, especially before symptoms. Studies also moved forward newborn screening feasibility and more objective ways to track disease using MRI and video-based measures. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Earlier donor transplant. Long-term data made the timing of pre-symptomatic HSCT look especially important.
- Family support needs. Reports added specific details about how MLD affects the whole household.
- Tracking progression. New tools aimed to make measurement more consistent, while other work warned about MRI interpretation traps.
- Earlier diagnosis. Reports described practical screening pathways and highlighted situations where diagnosis is not straightforward.
- Whole-body risks. The months covered added detail on health issues beyond the nervous system and on risks during serious infections.
New
September 2026
- Transplant timing. Earlier donor stem cell transplant was linked to better daily function.
- Ongoing symptoms. Transplant did not always stop symptoms from getting worse.
- Gallbladder changes. Gallbladder changes were often reported across different MLD stages.
August 2026
- Motor score tracking. AI scored motor function from videos, tested on visits where experts agreed.
- Newborn screening model. A US model projected earlier detection and better motor outcomes.
- De-identified video outlines. Videos were turned into stick-figure outlines before scoring.
July 2026
- COVID hospitalizations. MLD was linked to higher odds of COVID-19 hospitalization.
- Hospital survival. Survival after hospitalization was similar to controls in the lysosomal disorder group overall.
- Newborn screening steps. A step-by-step newborn screening approach worked, but retesting was common.
- Long-term follow-up. Experts described long-term monitoring after autologous stem cell gene therapy.
June 2026
- Brain volume patterns. Many brain regions were similar in size, or larger, in MLD.
- Brain fluid spaces. Enlarged fluid spaces in the brain were common in MLD.
- Age-based comparisons. Growth charts compared MRI volumes with typical age-related brain growth.
May 2026
- More responsibility at home. Some siblings were described as becoming more patient, mature, and caring at home.
- Difficult emotions. Parents also described siblings feeling fear, sadness, and anger.
- Effects on daily life and school. In some families, this distress was described as affecting day-to-day life, including school.
April 2026
- More consistent MRI scoring. A computer tool measured white‑matter damage on brain MRI in a more consistent way.
- MRI scores and movement. The MRI damage scores from this tool matched motor difficulties more closely.
- Tested on different MRI setups. The study included more than one MRI scan type, rather than relying on a single format.
March 2026
- MRI measures after HSCT. Specific MRI measurements at the time of HSCT were linked to different long-term courses in juvenile MLD.
- Baseline myelin damage. A higher demyelination burden at baseline was associated with a more severe progression.
- MLD-like pattern with normal enzyme. One case showed an MLD-like pattern even though arylsulfatase A enzyme activity was normal.
February 2026
- MRI reference changes. In MLD, MRI comparisons over time may be less straightforward because the inner skull space decreased while skull thickness increased, which can change how brain-size change is calculated in research.
- Daily caregiving time. In a small parent group, families described several hours per day of hands-on care, with major effects on work and social life.
- Time to diagnosis. From first concerns to diagnosis often took months, and early signs were most often motor changes that can be hard to interpret at first.
January 2026
- Similar symptoms. Late-onset MLD can look like multiple system atrophy.
- ARSA gene testing. ARSA testing shifted one adult diagnosis from MSA to MLD.
- Gallbladder findings. One child had sulfatide buildup in gallbladder tissue.
Get the monthly update by email
Subscribe here to receive an email when a new monthly metachromatic leukodystrophy update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).